Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 372% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- Strong ROE of 26.2% with 20.3% net margin
- Revenue growing at 7% annually
WATERS CORP /DE/ (WAT) is a Healthcare company operating in Laboratory Analytical Instruments, listed on the NYSE , with a market capitalisation of $29.3 billion . Key value metrics: P/E ratio 43.8, P/B ratio 11.45, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
WATERS CORP /DE/ — Fundamental Analysis Summary
WATERS CORP /DE/ (WAT) is currently trading 372% above its Graham Number of $63.35, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 43.8x.
On financial health, WAT shows a moderate Piotroski F-Score of 4/9, and strong return on equity of 26.2% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.55.
StockPik's composite Value Score for WAT is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
WAT reports a high gross margin of 61.0% (sector average: 33.5%) and a strong operating margin of 25.5%.
WAT shows revenue growing at 7% year-over-year, with earnings growing at 1%.